Table 3 Changes in secondary outcomes (V3−V1)

From: Efficacy and safety of the probiotic Lactobacillus paracasei LP-33 in allergic rhinitis: a double-blind, randomized, placebo-controlled trial (GA2LEN Study)

Secondary parameters Placebo LP-33 P-value
RTSS-5 global score −2.46 (3.57) −2.70 (3.48) 0.1288
RQLQ—‘Nose symptoms’ domain −1.80 (1.61) −1.89 (1.66) 0.4622
RQLQ—‘Eye symptoms’ domain −1.36 (1.77) −1.75 (1.63) 0.0029
Time to first exacerbation of symptoms (d) 10.63 (4.63) 10.50 (5.04) 0.6473
Well-being VAS −2.81 (3.03) −3.17 (2.97) 0.4958
RTSS-5—nasal symptoms −1.95 (2.86) −2.15 (2.89) 0.1783
RTSS-5—ocular symptoms −0.50 (0.92) −0.56 (0.85) 0.0700
  1. Abbreviations: RQLQ, rhinitis quality of life; RTSS, rhinitis total symptom score; VAS, visual analogue scale.
  2. Values are means (s.d.).
  3. Between-group comparison on V3−V1 variation, P<0.05.